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Abstract 
Background: Obesity has tremendous impact on the health systems. Its epigenetic bases are unclear. MacroH2A1 is 
a variant of histone H2A, present in two alternatively exon-spliced isoforms macroH2A1.1 and macroH2A1.2, regulat-
ing cell plasticity and proliferation, during pluripotency and tumorigenesis. Their role in adipose tissue plasticity is 
unknown.
Results: Here, we show evidence that macroH2A1.1 protein levels in the visceral adipose tissue of obese humans 
positively correlate with BMI, while macroH2A1.2 is nearly absent. We thus introduced a constitutive GFP-tagged 
transgene for macroH2A1.2 in mice, and we characterized their metabolic health upon being fed a standard chow 
diet or a high fat diet. Despite unchanged food intake, these mice exhibit lower adipose mass and improved glucose 
metabolism both under a chow and an obesogenic diet. In the latter regimen, transgenic mice display smaller pan-
creatic islets and significantly less inflammation. MacroH2A1.2 overexpression in the mouse adipose tissue induced 
dramatic changes in the transcript levels of key adipogenic genes; genomic analyses comparing pre-adipocytes to 
mature adipocytes uncovered only minor changes in macroH2A1.2 genomic distribution upon adipogenic differ-
entiation and suggested differential cooperation with transcription factors. MacroH2A1.2 overexpression markedly 
inhibited adipogenesis, while overexpression of macroH2A1.1 had opposite effects.
Conclusions: MacroH2A1.2 is an unprecedented chromatin component powerfully promoting metabolic health 
by modulating anti-adipogenic transcriptional networks in the differentiating adipose tissue. Strategies aiming at 
enhancing macroH2A1.2 expression might counteract excessive adiposity in humans.
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Background
The current pandemic in obesity/metabolic syndrome 
(with 30–50% of the overall population affected in the 
Western world) is a risk factor for many types of dis-
eases, including cardiovascular diseases and cancer. Epi-
genetic mechanisms of nuclear chromatin remodeling 
are increasingly recognized as crucial factors in the 
pathophysiology of obesity and related complications 
[1]. In fact, metabolic alterations in peripheral tissues 
are triggered at the cellular level by changes in gene 
transcriptional patterns dependent on the degree of 
nuclear chromatin compaction. The latter is regulated 
at several levels, allowing transcriptional plasticity. For 
instance, epigenetic marks such as DNA methylation 
are intensely investigated for their causal and associa-
tive role in the determination of body mass index (BMI) 
[2–4]. A recently emerged alternative mechanism of 
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transcriptional plasticity is the replacement of canoni-
cal histones, around which DNA is wrapped (H2A, H2B, 
H3 and H4), with the incorporation of histone variants, 
mostly of histones H2A or H3 [5–7]. The histone vari-
ant of H2A, known as macroH2A1, is believed to act as a 
strong transcriptional modulator that can either repress 
transcription or activate it in response to as yet unde-
fined nutrients or growth signals [8–13]. The impact of 
macroH2A1 on transcriptional processes has now come 
to take a center stage in the plasticity of stem cell differ-
entiation and in the pathogenesis of a growing number 
of cancer types [14–17]. MacroH2A1 is composed of a 
domain displaying 66% homology with histone H2A, 
and a domain called macro that is conserved in multiple 
functionally unrelated proteins throughout the animal 
kingdom and that can bind in  vitro with tight affinity 
ADP-ribose-like metabolites, providing a direct molecu-
lar interaction between intermediate metabolism and 
the chromatin, whereby a metabolite can tweak gene 
expression in vitro [18]. MacroH2A1 is in turn present in 
two alternatively exon-spliced isoforms, macroH2A1.1 
and macroH2A1.2, which differ for a few amino acids 
[18]. Whether these two isoforms play different roles in 
cell plasticity is debated and context dependent; how-
ever, most reports support a pro-differentiation role for 
macroH2A1.1 and an anti-differentiation and pro-pro-
liferative role for macroH2A1.2 [14–17, 19, 20]. Mice 
models, knockout (KO) for the whole macroH2A1 gene, 
have been reported. In KO mice generated in the pure 
C57BL/6  J background, modest developmental changes 
in macroH2A1-mediated gene regulation under a stand-
ard diet, and a very mild systemic protection against 
obesity upon a high fat regimen, were observed [21, 22]. 
By contrast, in KO mice for macroH2A1 generated in 
a mixed background a variable hepatic lipid accumula-
tion in 50% of the females has been described, without 
changes in body weight [23]. Therefore, despite compel-
ling in  vitro evidence that macroH2A1 modulates gene 
expression programs involved in cell metabolism, prolif-
eration and differentiation, the existing evidence for its 
role at the organism level upon nutritional stress, espe-
cially during fat accumulation obesity, is controversial. 
Moreover, data deriving from KO approaches might be 
often influenced by functional redundancy or compen-
satory effects between the isoforms. Under a standard 
diet, in SWR/J mice, featuring a higher metabolic health 
and a better triglyceride metabolism compared to com-
mon BALB/cByJ and C57BL/6J strains, a >threefold 
increase in hepatic basal mRNA levels of macroH2A1.2, 
among the top 15 upregulated genes, was found [24]. 
Conversely, in genetic or dietary mice models of non-
alcoholic fatty liver disease (NAFLD), a disorder that is 
present in 90% of obese subjects, the hepatic content of 
macroH2A1.2, but not of macroH2A1.1, is augmented 
[25].
The in vivo role of macroH2A1 isoforms in lipid metab-
olism and obesity is thus unclear. Here, we challenged 
newly generated macroH2A1.2–EGFP transgenic (Tg) 
mice [26] with an obesogenic high fat diet (60% energy 
from lard): Our findings identify macroH2A1.2 as a new 
and potent epigenetic inhibitor of adipogenesis. Its sys-
temic overexpression leads to a spectacular protection 
from obesity and its related complications. Mechanisti-
cally, macroH2A1.2 strongly impaired adipogenesis, both 
in vitro and in vivo.
Results
Differential association between macroH2A1.1 and 
macroH2A1.2 protein levels and BMI in human adipose 
tissue.
In various cell types, macroH2A1.1 displays an anti-
proliferation role, while macroH2A1.2 has an anti-differ-
entiation and pro-proliferative role [14–17, 19, 20]. Adult 
adipocytes are considered terminally differentiated cells. 
Here, we employed human visceral adipose tissue from 
obese subjects versus mildly overweight subjects to study 
the correlation between macroH2A1 isoform protein 
levels and body weight. Visceral adipose tissue biopsies 
were excised from patients with body mass index (BMI) 
ranging from 25 to 40, while they underwent abdomi-
nal surgery. Patient characteristics (sex, age, pathology) 
are described in Additional file 1: Supplementary Table I 
(Supplementary Material). Consistent with macroH2A1.2 
being expressed at low levels in differentiated tissues, 
immunoblotting analysis showed that it was barely 
detectable at high exposure in human adipose tissue 
(Fig.  1a). Conversely, macroH2A1.1 isoform was found 
expressed, with a trend toward higher levels in subjects 
with high BMI (30–40) compared to subjects with lower 
BMI (25–26, mildly overweight) (Fig.  1a). Consistent 
with human data, confocal immunofluorescence analy-
sis of white adipocytes in adipose tissue from wild-type 
mice revealed strong nuclear positivity (green) of mac-
roH2A1.1 and absence of macroH2A1.2 isoform (Fig. 1b, 
left). Immunoblotting analysis confirmed a very weak 
expression of macroH2A1.2 compared to macroH2A1.1 
in the adipose tissue (Fig. 1b, right).
MacroH2A1.2 transgenic (Tg) mice are leaner 
independently of food intake and energy expenditure
As human adult adipose tissue seems devoid of mac-
roH2A1.2, we sought to study the effect or reintroducing 
the protein by systemic transgenic overexpression. We 
used a fusion plasmid (pCX-MH2A/EGFP) consisting 
of a CAG promoter, a chimeric cDNA encoding mouse 
macroH2A1.2 (GenBank accession number AF171080) 
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and a fusion polypeptide with EGFP at the C termi-
nus of macroH2A1.2 to generate macroH2A1.2–EGFP 
transgenic (Tg) mouse lines by DNA microinjection into 
pronuclear stage embryos [26] (Fig.  2a). Tg mice were 
healthy and fertile, and green fluorescence could be 
detected neonatally throughout the body [26] (Fig.  2b). 
The fusion protein could be easily detected in nuclear 
extracts of internal organs such as the kidney and liver 
by immunoblot analysis: A band of 42 kDa was detected 
in both wild-type and Tg mice using an anti-macroH2A1 
antibody, whereas a band of 67 kDa was detected only in 
Tg organs, consistent with the expected size of the mac-
roH2A1.2–EGFP and detected with an anti-GFP anti-
body [26] (Fig. 2c). Endogenous macroH2A1.1 expression 
in these organs was not changed upon overexpression of 
macroH2A1.2–EGFP transgene (data not shown). In the 
visceral adipose tissue, macroH2A1.2 immunopositiv-
ity was detected by confocal microscopy in the Tg, but 
it was absent in wild-type mice (Additional file  2: Fig-
ure S1). Quantitative EchoMRI/CT scan showed that Tg 
mice were in average ~5% shorter than wild type (Fig. 3a, 
p < 0.0001), with ~20% less lean mass and ~fivefold lower 
fat mass (Fig. 3b, p < 0.0001). Consistently, macroH2A1.2 
Tg mice were also macroscopically leaner under a stand-
ard (chow) diet (Fig.  3c, upper panels). Similarly, when 
fed an obesogenic (12  weeks, 60% energy from lard 
[22]) high fat (HF) diet, macroH2A1.2 Tg mice appeared 
leaner and protected from fat induced-increased adipos-
ity to the naked eye (Fig. 3c, lower panels). Accordingly, 
body weight of age-matched Tg mice was strikingly lower 
than wild-type mice both under a chow diet (26.4 ± 0.9 
versus 33.9  ±  1.1, p  <  0.0001) and under a HF diet 
(36.3 ± 2.1 vs 44.9 ± 1.2, p < 0.0001) (Fig. 3d). Of note, 
the weight of macroH2A1.2 Tg mice fed an obesogenic 
HF diet was not statistically different than the base-
line one of wild-type mice fed a chow diet (36.3  ±  2.1 
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Fig. 1 Expression of macroH2A1 isoforms in human and mouse adipose tissue. a Left panel representative immunoblots of visceral adipose tissue 
(VAT) human biopsies from subjects with increasing BMI (25, 26, 27, 28, 30, 40), using antibodies against macroH2A1.1, macroH2A1.2 and H3. Right 
panel densitometric quantification of macroH2A1.1 levels normalized to H3 loading control as in the left panel, expressed as arbitrary units. b Left 
representative confocal images of adipose tissue sections immunolabelled for macroH2A1.1 or macroH2A1.2. MacroH2A1.1 (left panel, green) is 
highly expressed in mouse adipocytes, and higher magnification inset shows its subcellular localization in macrochromatin bodies and overlapping 
signals with DAPI (red) are shown in yellow. MacroH2A1.2 (right panel, green) appears not expressed in mice adipose tissue. Scale Bars 10 μm. Right 
representative immunoblots of visceral adipose tissue from three wild-type mice, using antibodies against macroH2A1.1, macroH2A1.2 and H3
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versus 33.9  ±  1.1, ns). These variations in body weight 
were mirrored by profound differences in the visceral 
adipose fat ratio as determined by EchoMRI/CT scan 
analysis (Fig. 3e): macroH2A1.2 Tg mice displayed more 
than threefold lower visceral adiposity compared to wild 
type fed a chow diet (8.6 ±  3.7 versus 26.5 ±  2, n =  8, 
p  <  0.0001). Consistently, under HF diet Tg mice accu-
mulated significantly less total visceral fat than wild-type 
mice (Fig. 3e). These large differences in body weight and 
adiposity could not be explained by a decrease in food 
intake in Tg animals, as both genotypes were found to 
eat the same amounts (Fig. 3f ). The respiratory exchange 
ratio (RER) is the ratio between the amount of CO2 
produced and O2 consumed by breathing. Measuring 
this ratio can be used for estimating which fuel (carbo-
hydrate or fat) is being metabolized to supply the body 
with energy. We observed significant increase in basal 
RER from 0.87 ±  0.03 in wild-type mice to 0.97 ±  0.01 
in macroH2A1.2 Tg mice (p < 0.05) (Fig. 3g), reflecting a 
switch from an energy consumption consisting of a mix 
of carbohydrates and fat to an energy consumption indic-
ative of carbohydrate being the predominant fuel source, 
in Tg animals. Upon a HF diet, wild-type animals had a 
decreased RER compared to chow diet fed littermates 
(0.78 ± 0.04, p < 0.05) indicating fat as the predominant 
fuel source, while Tg mice displayed a RER, 0.84 ± 0.01, 
similar to baseline wild-type levels, i.e., reflecting energy 
consumption combining carbohydrates and fat (Fig. 3g). 
IGF-1 blood levels were similar in wild-type and Tg mice 
indicating that differences in body weight and size were 
independent of IGF-1 (Fig. 3h). Overall, these data dem-
onstrate that macroH2A1.2 Tg have reduced total and 
visceral fat depots and an increased energy expenditure 
from carbohydrates.
MacroH2A1.2 Tg mice are more glucose tolerant 
and insulin sensitive, and display smaller pancreatic islets
In comparison with wild-type mice, an improvement in 
metabolic health is thus observed in Tg mice; we there-
fore also investigated the ability of Tg mice to respond to 
a glucose or insulin challenge. Basal glucose levels were 
considerably lower in Tg versus wild-type mice, fed a chow 
(124.9 ± 11.4 versus 147.25 ± 8.86, p < 0.05) or a HF diet 
(155.67 ± 10.6 versus 190 ± 11.3, p < 0.0001) (Fig. 4a, b). 
In glucose tolerance tests (GTT), glucose levels remained 
significantly lower in macroH2A1.2 Tg mice at every time 
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Fig. 2 MacroH2A1.2-GFP transgenic mice (adapted from [26], licence no. 3766141157990). a Structure of the vector expressing macroH2A1.2–EGFP 
(pCXMH2A/EGFP). Mouse macroH2A1.2 tagged with EGFP was expressed under the control of the CAG promoter with a cytomegalovirus early 
enhancer element and a chicken b-actin promoter. b Stereomicroscopic analysis. The macroH2A1.2–EGFP transgenic mouse (Tg) shows green 
fluorescence in the skin. The white line marks the position of a wild-type mouse. c Immunoblot analysis. Nuclear extracts (10 µg/lane) of liver (L) and 
kidney (K) were prepared from wild-type (WT) and transgenic (Tg) female mice and analyzed using anti-GFP and anti-macroH2A1 antibodies
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point, compared to wild-type littermates, both upon a 
chow or a HF diet (Fig. 4a). Insulin tolerance tests (ITT) 
showed that the insulin-mediated decrease in glycemia 
was much more pronounced and statistically significant 
in Tg mice versus wild-type mice at every time measured 
(p  <  0.0001 at 15, 30, 45, 60, 120  min time points) upon 
a chow diet (Fig.  4b). Upon a HF diet, statistical differ-
ences were observed between macroH2A1.2 Tg and wild-
type mice only after 30 min (Fig. 4b). To gain insight into 
the mechanism by which systemic glucose tolerance is 
improved in chow and HF diet fed macroH2A1.2 Tg mice, 
we characterized insulin-induced AKT signaling in the 
skeletal muscle, liver and adipose tissues under insulin-
stimulated conditions (0.75 U kg − 1 body weight, injected 
15 min before killing) (Additional file  3: Figure S2). AKT 
phosphorylation (Ser473) was increased in insulin-respon-
sive peripheral tissues of macroH2A1.2 Tg mice fed either 
a chow or a HF diet compared with wild-type controls 
(Additional file 3: Figure S2). Circulating insulin levels did 
not differ between genotypes under a chow diet, and they 
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Fig. 3 Metabolic phenotyping of macroH2A1.2 Tg mice. a CT scan of a representative WT and macroH2A1.2 Tg mouse (upper panels), image-
assisted quantification of body length (lower panel); b lean and fat masses were determined by CT scan c representative pictures of WT and 
macroH2A1.2 Tg mice fed a chow diet (upper panels) or a HF diet (lower panels) mice, with a dorsal view (left panels) and a ventral view of peritoneal 
cavity showing internal organs upon killing (right panels); d body weight in WT and macroH2A1.2 Tg mice fed a chow or a HF diet at the experimen-
tal end point; e visceral fat ratio as determined by EchoMRI/CT scan in the four mice groups; f food intake in the four mice groups was assessed; 
g respiratory CO2/O2 exchange ratio as determined by metabolic cages; h IGF-1 blood levels, measured by ELISA (Milliplex) upon killing. Data are 
expressed as means} S.E.M. (n = 8–9 per group). *p < 0.05, ***p < 0.001 change versus WT fed a chow diet; ##p < 0.01 change versus WT fed a HF 
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were found increased to the same extent upon HF diet 
(Fig. 4c). However, pancreatic islets were strikingly smaller 
in macroH2A1.2 Tg compared to wild-type mice (Fig. 4d, 
left panels); semi-quantitative double immunofluorescence 
confocal analysis in pancreatic islets showed a similar 
insulin content in beta cells in both genotypes, with a not 
significant trend toward a decreased glucagon content in 
alpha cells in Tg mice (Fig. 4d, right panels). Hence, mac-
roH2A1.2 Tg mice are more glucose tolerant and insulin 
sensitive, and display smaller pancreatic islets.
MacroH2A1.2 Tg mice have decreased hepatic 
and pancreatic fat content and inflammation upon a HF 
diet
Obesity is almost invariably associated with NAFLD and 
to non-alcoholic fatty pancreas disease (NAFPD), two 
interrelated conditions characterized by parenchymal tri-
glyceride accumulation and inflammation. NAFLD and 
NAFPD are risk factors to develop cirrhosis and cancer 
[1, 27]. We sought to analyze the lipid content in the liver 
of macroH2A1.2 Tg versus wild-type mice: H&E stain-
ing revealed evident differences, with a total protection 
from lipid accumulation in Tg compared to wild-type 
animals that developed instead extensive mixed micro/
macro/vesicular NAFLD upon HF diet (Fig. 5a, left pan-
els). Accordingly, NAFLD and lobular inflammation 
scores were highest in livers of wild-type mice fed a HF 
diet; conversely, NAFLD score of Tg animals upon HF 
diet was similar to the one of wild-type mice fed a chow 
diet (Fig.  5a, right panels). H&E staining of pancreata 
revealed a marked decrease in fat infiltration in Tg mice 
versus wild-type mice (Fig.  5b, left panels). Histological 
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analysis revealed also that upon a chow diet, wild-type 
mice contained ~5% of intralobular fat, while Tg mice 
were devoid of it; upon a HF diet, Tg mice accumulated 
only <5% of intralobular fat, while pancreata from wild-
type mice displayed ~25% intralobular, ~1–2% interlob-
ular fat accumulation and ~2 of Mathur score (Fig.  5b, 
right panels). MacroH2A1.2 Tg mice are thus protected 
against HF-induced NAFLD and NAFPD, consistent with 
their protection from obesity.
macroH2A1.2 counteracts adipogenesis in vivo and in vitro
Our data indicate that macroH2A1.2 Tg mice do not dis-
play important differences in food intake as compared 
to wild-type mice. We thus hypothesized that the strik-
ing protection from obesogenic diet-induced increase 
in body weight and adiposity in these animals could be 
attributed to an inhibition of adipogenesis. Adipocytes 
are the major storage site for fat in the form of Tgs, 
and this can be accomplished in two different ways, by 
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Page 8 of 19Pazienza et al. Epigenetics & Chromatin  (2016) 9:45 
expanding the available adipose cells or by recruiting new 
fat cells upon differentiation. Histological analyses of vis-
ceral white adipose tissues revealed a ~60% decrease in 
adipocyte size (area) in Tg mice versus wild-type mice 
even upon a chow diet (Fig. 6a). Upon a HF diet, Tg ani-
mals displayed adipocytes on average ~35% smaller than 
wild type (Fig. 6a). Variations in the circulating concen-
tration of adipose tissue-secreted adipokine leptin in the 
four mice groups correlated well with the size of body 
fat stores (Fig.  6b). To explore the molecular mecha-
nisms that might be involved in the decreased adiposity 
of macroH2A1.2 Tg mice, we used a gene array profiling 
the expression of 84 key genes involved in white adipose 
tissue adipogenesis, including hormones, adipokines, 
enzymes and transcription factors. Using a twofold cut-
off difference in mRNA expression upon HF diet in either 
of the two groups of animals, we identified 20 genes, 18 
of which were oppositely regulated in the adipose tissue 
of macroH2A1.2 Tg mice compared to wild-type mice 
(Fig.  6c, Additional file  1: Supplemental Table III). Pro-
differentiation and pro-adipogenic genes ACACB, AGT, 
FASN, RETN and SLC2A4 were significantly upregulated 
in wild-type adipose tissue and downregulated in mac-
roH2A1.2 Tg adipose tissue when mice were fed a HF 
diet (Fig.  6c). Conversely, anti-adipogenic genes E2F1, 
EGR2, JUN, LMNA, anti-inflammatory genes SIRT1, 
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Fig. 6 a Left representative pictures from hematoxylin and eosin staining of visceral white adipose tissue sections in wild-type (WT) and mac-
roH2A1.2 Tg (Tg) mice fed with a HF diet. Right quantification of adipocyte area (μm2). b Leptin blood levels, measured by ELISA (Milliplex) in the 
four mice groups upon killing. Data are expressed as mean ± S.E.M. (n = 8–9 per group). *p < 0.05, ***p < 0.001 change versus WT fed a chow diet; 
#p < 0.01 change versus WT fed a HF diet. c Adipose gene expression profiling expressed in fold change and relative to HF diet compared to chow 
diet either in WT or in Tg mice. Results are represented as means of 3 mice per condition (WT, WT + HF diet, Tg, Tg + HF diet). All differences, with 
the exception of BMP7 and WNT5B (not significant), are highly significant (p < 0.0001)
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SIRT2, thermogenic gene UCP1 and proliferation-reg-
ulating genes ANGPT2, CCND1, CDKN1A, CDKN1B, 
were upregulated in macroH2A1.2 Tg adipose tissue and 
downregulated in wild-type adipose tissue when mice 
were fed a HF diet (Fig.  6c). BMP7 and WNT5B were 
found two–threefold upregulated in the adipose tissue of 
both genotypes upon a HF diet (Fig. 6c, d). To understand 
whether macroH2A1.2 could affect the differentiation of 
pre-adipocytes into mature adipocytes, we used the well-
established murine 3T3-L1 cell model. Stable expres-
sion of GFP, macroH2A1.2, and its sister splicing variant 
macroH2A1.1, in 3T3-L1 pre-adipocytes was achieved 
by lentiviral transduction as previously described [12], 
and differentiation into mature adipocytes was obtained 
through a 15  days long protocol based on the sequen-
tial addition of dexamethasone, IBMX and insulin [28] 
(Fig. 7a). Expression of macroH2A1.1 transgene did not 
have an effect on endogenous macroH2A1.1 protein lev-
els that were stable along differentiation (day 1–5–15, 
Additional file  4: Figure S3). Conversely, expression 
of macroH2A1.1 and macroH2A1.2 transgenes led to 
markedly decreased levels of endogenous macroH2A1.2 
at all time points of the differentiation protocol, com-
pared to GFP-expressing control cells (Additional file 4: 
Figure S3). Of note, in GFP-expressing control cells 
macroH2A1.2 endogenous levels decreased during the 
differentiation of pre-adipocytes into adypocytes (day 5 
and day 15 compared to day 1, Additional file  4: Figure 
S3), which is consistent to the low levels of macroH2A1.2 
in adult human and mouse VAT (Fig. 1). At the end point 
of the protocol, mature 3T3-L1 adipocytes were ana-
lyzed for lipid content using Oil Red O (ORO) staining: 
We found that, compared to GFP-overexpressing cells, 
macroH2A1.2-GFP-overexpressing cells displayed a 
~2.5-fold decrease in lipid content, while macroH2A1.1-
overexpressing cells accumulated ~1.7-fold more lipids 
(Fig. 7b). MacroH2A1.2-dependent mRNA upregulation 
of RETN, E2F1 and EGR2, together with downregulation 
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Fig. 7 a Schematic protocol for 3T3-L1 differentiation from pre-adipocytes into mature adipocytes [28]. b Left panels 3T3-L1 pre-adipocytes with 
lentiviral-mediates stable expression of GFP, macroH2A1.1-GFP and macroH2A1.2-GFP were induced to differentiate into mature adipocytes as in 
(a). At the 15th day of differentiation, cells grown on coverslips were stained with Oil Red O (ORO) solution and counterstained with DAPI for nuclei. 
ORO was visualized with fluorescence microscopy. Right panel the percentage of ORO-stained cells was quantified over the total of GFP/DAPI-posi-
tive cells, averaging 10 different random fields in 3 separate experiments. Results are represented as mean ± S.E.M. ***p < 0.001 change versus GFP
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of FASN, was observed in 3T3-L1 adipocytes, mirror-
ing the in vivo data (Additional file 5: Figure S4). In vitro 
and in  vivo data collectively suggest that macroH2A1.2 
might impair adipocyte differentiation while, in the 3T3-
L1 model, overexpression of macroH2A1.1 leads to aug-
mented lipid accumulation. Interestingly, macroH2A1.1 
has been consistently reported to be highly expressed 
and have an anti-proliferative action, while macroH2A1.2 
was expressed at low levels, in differentiated cells [14]. 
Consistently, confocal immunofluorescence analysis of 
adult heart tissue, which is slowly or not proliferating 
and possesses scarce regenerative capacity, in WT mice 
fed a chow diet revealed predominant expression of mac-
roH2A1.1 and not of macroH2A1.2 (Additional file  6: 
Figure S5). In contrast, under the same conditions the 
adult mouse liver, which is a regenerative organ mainly 
due to the high proliferation rate of hepatocytes, both 
macroH2A1.1 and macroH2A1.2 are expressed (Addi-
tional file 6: Figure S5).
Genome occupancy of macroH2A1.2 display minor 
changes upon adipocyte differentiation
We sought to analyze if changes in chromatin occupancy 
macroH2A1.2 might play a role in transcriptional changes 
associated with adipocyte differentiation in  vitro. We 
used ChIP-Seq, using a ChIP grade anti-GFP antibody, 
to isolate and sequence genomic regions associated with 
macroH2A1.2-GFP chimeric protein. No antibody was 
used as a negative control to subtract aspecific peak dis-
tribution. The data discussed in this publication have 
been deposited in NCBI’s Gene Expression Omnibus 
and are accessible through GEO Series accession num-
ber GSE85796 (https://www.ncbi.nlm.nih.gov/geo/query/
acc.cgi?acc=GSE85796). Both pre- and post-3T3-L1 adi-
pocyte differentiation, macroH2A1.2-associated reads 
displayed a bell shape distribution with a peak at about 
−7000–8000 bp upstream of TSS (Additional file 7: Figure 
S6). Similar binding affinity of macroH2A1.2 histone was 
observed in mature adipocytes and in pre-adipocytes, as 
determined by sequence read tag density (Fig. 8).
Binding sites were subsequently grouped by gene 
section, i.e., 3′ or 5′ untranslated region (UTR), cod-
ing sequence, intergenic, intron, TTS, non-coding and 
promoter-TSS (Fig.  8b). The frequency of occupancy 
showed that macroH2A1.2 binding was enriched in 
intergenic and intron regions, with no significant differ-
ences between pre- and post-differentiation conditions 
(Fig. 8b, upper panels). Similarly, filtering binding sites to 
exclude intergenic and intron regions, in order to high-
light exons, TTS, 5′UTR, noncoding, promoter-TSS and 
3′ UTR, did not evidence differences in binding patterns 
(Fig. 8b, lower panels). Analysis of genome occupancy of 
the pro- and anti-adipogenic genes (ACACB, AGT, FASN, 
RETN, SLC2A4, E2F1, EGR2, JUN, LMNA, SIRT1, SIRT2, 
UCP1, ANGPT2, CCND1, CDKN1A and CDKN1B) under 
the control of macroH2A1.2 in  vivo (Fig.  6c) identified 
enriched regions (binding sites) with a false discovery rate 
(FDR) <0.01 only in 4 genes (UCP1, CDKN1A, FASN, 
Slc2a4), which were though inconsistent between biologi-
cal duplicates and were not significantly different between 
3T3-L1 pre-adipocytes and in 3T3-L1 mature adipocytes 
(Fig. 9 and data not shown). To gain a more general view, 
macroH2A1.2-bound genes in 3T3-L1 cells in ChIP-Seq 
were represented by Circos plots (Fig.  10a). Zooming to 
represent magnifications of example chromosomes 5, 7 
and X uncovered that with the exception of few distinct 
regions macroH2A1.2 significant genomic binding pat-
terns in pre-adipocytes and in mature adipocytes were 
very similar (Fig.  10b–d). Our genomic analysis thus 
showed that the process of differentiation induces mod-
est changes in macroH2A1.2 genome occupancy that may 
not account for its transcriptional effects in fat cells.
We then hypothesized that macroH2A1.2 could mod-
ulate transcription through the recruitment/modula-
tion of the activity of transcription factors (TF). We thus 
examined the binding region sequences within the two 
datasets (3T3-L1 pre- and post-differentiation) to search 
overrepresented binding motifs for TF that might play 
a role in mediating macroH2A1.2-dependent effects. 
To this aim, we used PscanChIP tool that, starting from 
a collection of genomic regions, evaluates both motif 
enrichment and positional bias within them. Interest-
ingly, in both pre-adipocytes and in mature adipocytes 
paired box  4 (PAX4) ranked as the most enriched TF 
presenting a binding matrix among macroH2A1.2-
binding regions (Fig.  11a). GATA-binding sites were 
overrepresented in pre-adipocytes (Fig.  11a). In addi-
tion to the common matrices enriched in both pre- and 
post-differentiation adipocytes (including the master TF 
regulator of adipogenesis PPARγ), we observed several 
matrices specifically overrepresented in either pre-adi-
pocytes (NFIC:TLX1, PKNOX1, TGIF2, TGIF1, ESR1, 
GATA3, PKNOX2, ZBTB18, TFEC and BHLHE41) or 
mature adipocytes (RXRA::VDR, Gmeb1, Prrx2, FEV, 
SP4, PROP1, NEUROG2, TEAD4, TP53 and SCRT2) 
(Fig.  11b). Of note, anti-adipogenic RXRA::VDR and 
TP53 were overrepresented specifically in mature 
macroH2A1.2-overexpressing adipocytes. Several of the 
TFs emerging from the analysis are known to bind to 
homeobox genes (NFIC:TLX1, PKNOX1, TGIF1, TGIF2, 
PKNOX2 in pre-adipocytes; Prrx2 and PROP1 in mature 
adipocytes) (Fig. 11b). Other binding matrices identified 
TF that function in neural/muscular/bone developmental 
programs (ZBTB18, TFEC, BHLHE41 in pre-adipocytes, 
and GMEB1, SP4, NEUROG2, TEAD4 and SCRT2 in 
mature adipocytes), likely associating to transcriptional 
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repression neighboring macroH2A1.2 binding in adi-
pose cells (Fig. 11b). These data demonstrate that, despite 
minor changes in genomic occupancy, macroH2A1.2 
might associate with different TF-binding sites upon adi-
pocyte differentiation, suggesting a potential transcrip-
tional mechanism.
Discussion
Obesity and obesity-related disorders are attaining 
pandemic proportions with more than a third of the 
population living in Western countries, with profound 
repercussions on the health systems. Epigenetic mecha-
nisms are key players in the pathophysiology of obesity 
Fig. 8 a Violin plots representing the density of reads pre- and post-adipogenic differentiation (pre-adipocytes and mature adipocytes, respec-
tively), calculated with the formula: tag density = count/region length × 100 as log2 values. b Pie charts with annotation of the genomic regions 
displaying significant binding sites for macroH2A1 in pre-adipocytes and in mature adipocytes. TTS transcription termination site; TSS transcription 
starting site; 3′UTR 3′ untraslated region. Most of the macroH2A1.2 occupancy is intergenic or in introns (upper pies): lower pies include only the 
unrepresented genomic binding patterns of macroH2A1.2 (TTS, promoter-TSS, 5′UTR, 3′UTR, noncoding)
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and related complications. Among these mechanisms, 
canonical histones can be replaced with histone variants 
that alter chromatin structure and DNA accessibility.
MacroH2A1 is a histone variant of histone H2A pre-
sent in two spicing isoforms, macroH2A1.1 and mac-
roH2A1.2, playing diverse roles in cell differentiation 
and plasticity [8–11, 14–18]. Previous conflicting evi-
dence showed that histone variant macroH2A1 whole 
gene transcriptional activity either favors lipid accu-
mulation [22] or it may be protective against it [21, 23], 
in either cases with a mild phenotype. This is the first 
study showing that macroH2A1.2 isoform strongly pro-
tects against HF-induced obesity. Mice bearing a chi-
meric macroH2A1.2-GFP transgene displayed drastically 
reduced total and visceral adiposity compared to their 
wild-type littermates both upon a chow or a HF diet. 
Obesity-induced liver and pancreatic damages in terms 
of fat accumulation and inflammation were completely 
wiped out by macroH2A1.2 transgene in mice which 
looked healthy as the wild type fed a chow diet, without 
differences in food intake. Tg mice typically relied on a 
mix carbohydrate/fat burn for energy consumption, 
while wild-type animals relied rather on fat consumption, 
which could be explained by the very low levels of basal 
body adiposity in Tg mice. MacroH2A1.2 Tg mice were 
also slightly shorter than controls; however, we did not 
find differences in IGF-1 levels, which are implicated in 
growth and adiposity extent in mice [29]. Tg mice were 
also, to a large extent, more insulin sensitive and glu-
cose tolerant than wild-type mice. The reduced size of 
pancreatic islets in Tg mice is reminiscent of a caloric 
restriction regimen [30]. Glucagon levels are often dis-
rupted in obese individuals: accordingly, the number of 
glucagon-producing α-cells was perturbed in wild-type 
but not in Tg mice when fed a HF diet. Altogether, these 
strong evidences of metabolic health unrelated to altera-
tions of food intake or GH/IGF-1 axis led us to hypoth-
esize that the leanness of the Tg mice might be intrinsic 
to the adipose tissue and due to reduced adipogenesis at 
the molecular level. Reduced adipogenesis could trans-
late into less circulating fat and triglycerides that might 
damage other peripheral organs such as the liver and 
the pancreas, without directly impinging on energy 
expenditure and hunger. Expression analysis of mRNA 
transcripts implicated in adipogenesis uncovered down-
regulation of pro-adipogenic genes ACACB, AGT, FASN, 
RETN and SLC2A4 and upregulation of anti-adipogenic 
genes E2F1, EGR2, JUN, LMNA, anti-inflammatory genes 
SIRT1, SIRT2, thermogenic gene UCP1 and pro-prolif-
erative genes ANGPT2, CCND1, CDKN1A, CDKN1B in 
macroH2A1.2 Tg mice, which is consistent with a reduc-
tion of adipocyte mass and with a potential expansion of 
the undifferentiated pre-adipocyte cellular pool. Consist-
ently, macroH2A1.2-GFP-overexpressing 3T3-L1 pre-
adipocytes showed strongly reduced lipid content upon 
differentiation into adipocytes, as observed in Tg mice. It 
Fig. 9 Genome browser (University of California Santa Cruz, UCSC) graphic representation of UCP1 and CDKN1A genes. Bigwigs in blue and red 
indicate peak distributions—reflecting macroH2A1.2 binding—in 3T3-L1 pre-adipocytes and in 3T3-L1 mature adipocytes, respectively, in biological 
duplicates. Bigwigs in black indicate aspecific peak distribution [no antibody (Ab), negative control]. Black bars indicate enriched regions (binding 
sites) with a false discovery rate (FDR) <0.01
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is has been shown that 3T3-L1 cell differentiation asso-
ciates with genome-wide epigenetic dynamic changes in 
the DNA demethylation/methylation ratio in a time- and 
stage-dependent manner [31]; DNA hypomethylating 
agent decitabine blocked the 3T3-L1 adipogenic process 
[31]. In the context of cancer cells, macroH2A1 incorpo-
ration antagonizes the anti-proliferative effects of decit-
abine [12, 13]. We postulate that macroH2A1.2 might 
interfere with DNA methylation events during the adipo-
genic gene expression program.
Surprisingly, stable overexpression of macroH2A1.1, 
the second splicing variant of macroH2A1 gene, yielded 
opposite effects, with large lipid accumulation upon dif-
ferentiation. Our data in mice and humans suggest also 
that adipose tissue display endogenous low or absent 
expression of macroH2A1.2, while macroH2A1.1 is 
present, and its levels increase upon a HF diet-induced 
obesity in mice, and in obese compared to mildly over-
weight individuals; however, these patients were enrolled 
for other pathologies and this could have an impact on 
the expression of macroH2A1 isoforms. Since depletion 
of the whole macroH2A1 gene [22] has also, although 
milder, anti-adipogenic effects in mice fed a HF diet, we 
argue that macroH2A1.1 has a stronger pro-adipogenic 
role than the protective one of macroH2A1.2. Gen-
eration of macroH2A1.1 transgenic murine models will 
prove its mechanistic role and tissue-specific interac-
tion with macroH2A1.2 during the development of obe-
sity in  vivo. Genome-wide distribution of macroH2A1 
histone variants in mouse liver chromatin indicate that 
macroH2A1 functions primarily as a repressor in adult 
liver [32].
Fig. 10 Representation of commonly and differentially bound genes in ChIP-Seq by Circos plots. a Circos plot of the whole 3T3-L1 cells genome, 
representing in the inner circle (in red) macroH2A1.2 significant binding regions in mature adipocytes, in the middle circle (in black) macroH2A1.2 
significant binding regions in pre-adipocytes are represented and in the outer circle all chromosomes together with the localization of the 20 genes 
analyzed in Fig. 6. b, c and d represent magnifications of chromosomes 5, 7 and X, respectively, as in (a). Black arrows point to chromosomic regions 
differentially bound by macroH2A1.2
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Variations in macroH2A1 transcriptional activities 
to a large extent independent of genome occupancy in 
response to nutritional and DNA methylation status have 
been reported in cancer cells [9, 11, 12]. Consistent with 
these studies, our ChIP-Seq analyses comparing mac-
roH2A1.2 Tg genome binding between 3T3-L1 pre-adi-
pocytes and 3T3 post-differentiated adipocytes revealed 
high degree of similarity in genome binding patterns, 
including within the bodies of the subset of genes involved 
in the adipogenic process that we analyzed. Variations in 
the expression and sequential binding patterns of key TF 
(GATA, C/EBPβ and −δ (C/EBPδ), PPARγ and C/EBPα) 
function in the adipogenic differentiation program. Our 
in silico analysis of TF-binding sites in proximity of mac-
roH2A1.2 genome binding revealed that GATA-binding 
sites were overrepresented in the proximity of mac-
roH2A1.2 binding in 3T3-L1 pre-adipocytes compared 
to differentiated cells, consistent with their role in adipo-
cyte precursors and with their downregulation setting the 
stage for terminal differentiation. In mature adipocytes, 
RXRA::VDR and TP53-binding sites were enriched, which 
might reflect their anti-adipogenic transcriptional effects 
[33, 34]. The enrichment of consensus sequences for TF 
controlling homeobox genes, including the overrepre-
sented PAX4, in macroH2A1.2 associates chromatin reads 
in the context of adipocyte differentiation deserves fur-
ther investigation. In addition to potential dynamic inter-
actions with TFs, it is unclear how posttranscriptional 
modifications might affect histone variants function with-
out changes in occupancy. Adipose tissue is at the nexus 
ba
NAME ID 
NFIC::TLX1 MA0119.1 
PKNOX1 MA0782.1 
TGIF2 MA0797.1 
TGIF1 MA0796.1 
ESR1 MA0112.1 
GATA3 MA0037.2 
PKNOX2 MA0783.1 
ZBTB18 MA0698.1 
TFEC MA0871.1 
BHLHE41 MA0636.1 
NAME ID 
RXRA::VDR MA0074.1 
Gmeb1 MA0615.1 
Prrx2 MA0075.1 
FEV MA0156.1 
SP4 MA0685.1 
PROP1 MA0715.1 
NEUROG2 MA0669.1 
TEAD4 MA0809.1 
TP53 MA0106.3 
SCRT2 MA0744.1 
Pre-adipocytes – all TF 
Mature adipocytes – all TF 
Pre-adipocytes – specific TF 
Mature adipocytes – specific TF 
Fig. 11 a Tables representing the enrichment for binding sites of known transcription factors (TF) in macroH2A1.2-binding regions in pre-adipo-
cytes (left) and mature adipocytes (right). In each table, the left column contains gene names, the middle column indicates the matrixes generated 
through PscanChIP and the right column contains the p value. b Tables illustrating the TF-binding sites, best hits among the first one hundred, not in 
common, e.g., specifically enriched in pre-adipocytes or in mature adipocytes
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of processes involved in health span and metabolic dys-
function: Progression of age-related fat tissue dysfunction 
follows different trajectories across different fat depots, 
with fat becoming redistributed from subcutaneous to 
intraperitoneal depots and ultimately ectopic sites. This 
is associated with metabolic disturbances. The pre-adipo-
cytes from which new fat cells develop switch into a pro-
inflammatory, tissue-remodeling state in old age, instead 
of differentiating into fat cells [35]. In cellular senescence, 
proliferation becomes arrested and cells acquire a pro-
inflammatory senescent secretory phenotype (SASP), 
with release of chemokines and cytokines [35]. We and 
others have shown that macroH2A1.1 ectopic expression 
sustains SASP in fibroblasts and hepatoma cells [12, 36]; a 
similar signaling loop might take place in the adipose tis-
sue. How to boost macroH2A1.2 expression/activity, to 
the detriment of macroH2A1.1, with an anti-obesity ther-
apeutic purpose? Some of the switch factors controlling 
macroH2A1 splicing into macroH2A1.1 or macroH2A1.2 
isoforms have been identified in cancer cells: QKI and 
RNA helicases Ddx17/Ddx5 [37, 38]. Epigenetic splicing 
regulatory strategies are already being explored for can-
cer therapy and might hold also a potential against obesity 
and its related complications.
Conclusions
Histone variant macroH2A1.2 is an unprecedented chro-
matin component that, if overexpressed, inhibits pro-
adipogenic transcriptional programs, fat deposition and 
massively protects mice from high fat diet-induced obe-
sity. Given that this histone is not expressed in human 
differentiated adipose tissue, it is possible to envisage that 
strategies aiming at its reintroduction in fat tissues could 
pave the way for new anti-obesity therapies.
Methods
Human biopsies
Seven patients with BMI from 25 to 40 were enrolled 
(Additional file  1: Supplementary Table I, Supplemen-
tary Material). Patient underwent surgical procedures 
(Whipple’s, right hepatectomy, wedge resections of the 
liver) according to conditions including pancreatic ade-
nocarcinoma and colorectal liver metastases. Informed 
consent was obtained from each patient. Procedures to 
extract adipose tissue biopsies were performed through 
incision that depended on the type of operation, trans-
verse abdominal for pancreas, midline or inverted L 
shape for liver. The incision of the skin was performed 
with the blade knife until the subcutaneous tissue 
was visualized. Around the umbilicus, a small part of 
the subcutaneous fat (0.5  cm3) was resected with the 
scissors. Specimens were frozen at −80  °C before fur-
ther characterization by immunoblotting. The study 
was approved by the UCL Royal Free Biobank Ethi-
cal Review Committee (NRES Rec Reference: 11/
WA/0077). Tissues were processed in accordance 
with the UCL Royal Free Biobank protocols under the 
Research Tissue Bank Human Tissue Act licence, prior 
to use in research [39].
Animals
The MacroH2A1.2–EGFP transgenic mouse line estab-
lished by Soma et al. [26] was backcrossed to C57BL/6 J 
for 5–6 generations. Tg mice positive for the transgene 
were identified by PCR amplification from tail tissue 
genomic DNA, using the primers 5′-TGACAGAAA-
GCTGAAATCCATCGC-3′ and 5′-TCCAGCAGGAC-
CATGTGATCGC-3′, and by observing whole-body 
EGFP fluorescence using a UVL-56 handheld UV lamp 
(UVP, Cambridge, UK or Upland, CA, USA). All experi-
ments were approved by Tottori University Ethical Com-
mittee, were performed using heterozygous transgenic 
mice and were carried out according to the Guide for the 
Care and Use of Laboratory Animals of Tottori Univer-
sity. Six-week old wild-type (WT) and transgenic (Tg) 
mice were assigned into 4 groups (8–9 mice/group): WT 
fed with chow diet, Tg fed with chow diet, WT fed with 
high fat (HF) diet and Tg fed with HF diet for 12 weeks. 
Obesogenic diet consist 60% energy from lard [22].
EchoMRI quantitative magnetic resonance and CT scan
EchoMRI™ quantitative magnetic resonance (QMR) 
technology was used to measure the body composition 
of live mice in terms of whole-body fat, and lean masses, 
according to manufacturer’s instructions: Measurements 
were made by placing live free moving mice into a thin 
wall plastic cylinder (4.7  cm, inside diameter; 0.15  cm 
thick) with freedom to turn about but limited to ~4 cm 
vertical movements by a plastic insert. After 2  min, 
when the measurement was completed, conscious mice 
returned to their home cage. Alternatively, CT scan-
ning was performed in isofluorane-anesthetized ani-
mals at 2-mm intervals from head to tail to determine 
body length, or from the diaphragm to the bottom of 
the abdominal cavity to determine visceral fat and liver 
fat content, using a LaTheta™ LCT 200 in  vivo micro-
CT scanner, according to manufacturer’s instructions 
(Hitachi, Aloka Medical, Japan).
Metabolic cages, glucose tolerance test (GTT) and insulin 
tolerance test (ITT)
In order to monitor in real time the metabolic gas 
exchange, groups of 8–9 mice per genotype on HFD 
were placed in indirect calorimetric cages where energy 
expenditure, food intake and activity were evaluated 
[22]: The whole-body energy metabolism in mice was 
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calculated in vivo as previously described [22]. GTT and 
ITT were performed as previously described [40].
Histology and immunofluorescence
Histological analyses and immunofluorescence staining 
are described in detail in the Additional file  1: Supple-
mentary Materials and methods.
Quantification of circulating cytokines
Insulin, leptin and IGF-1 levels were assessed in the sera 
of wild-type and macroH2A1.2 Tg animals, using a cus-
tomized mouse MILLIPLEX® MAP (multi-analyte pan-
els) Luminex system (Merck Millipore) [22], according to 
the manufacturer’s instructions.
Gene expression
A commercially available adipogenesis array (mouse RT-
Profiler array, Qiagen, Italy) was used to measure genes 
involved in adipogenesis by qRT‐PCR in mice visceral 
adipose tissue; expression data were normalized to the 
geometric mean of three house keeping genes (Actb, 
GAPDH and GusB). Briefly, after homogenization, tis-
sue RNAs were isolated using Trizol (1 ml per 100 mg), 
according to manufacturer’s protocol. RNA samples 
were purified using mini spin columns (Qiagen), quan-
tified using Nanodrop Spectrophotometer (Thermo 
scientific, UK). As for 3T3-L1 cell differentiation experi-
ments, the following QuantiTect primers (Qiagen) were 
used: FASN (QT00149240), RETN (QT00093450), EGR2 
(QT00160125) and E2F1 (QT01079106). qRT-PCR for 
determining gene expression in 3T3-L1 cells was per-
formed on 50  ng of purified RNA using the one-step 
QuantiFast SYBR Green RT-PCR kit (Qiagen) and the 
Mouse SYBR Green QuantiTect primer assay. All reac-
tions were set up in 96-well plates using a 7700HT Real-
Time PCR System (Applied Biosystems, Foster City, CA).
Western blot
Total and cytoplasmic/nuclear/histone proteins extrac-
tion and immunoblotting analyses were performed as 
previously described [12]. Primary antibodies were as 
follows: anti-GFP (Abcam, ab13970) anti-macroH2A1.1 
(Cell Signaling, Cat 12455), anti-macroH2A1.2 (Cell 
Signaling, Cat. 4827), anti-AKT (Cell Signaling, Cat. 
9272), anti-phosphoAKT-Ser473 (Cell Signaling, Cat. 
9271), anti-β-actin (Cell Signaling, Cat. 4967) and anti-
H3 (Cell Signaling, Cat. 9715).
Generation of stable clones of 3T3‑L1 cells: differentiation 
and lipid staining
Stable expression of macroH2A1.2 variant in 3T3-L1 
pre-adipocytes was achieved by lentiviral transduction 
as previously described [12]. Stable 3T3-L1 pre-adipo-
cytes were cultured to differentiate into mature adipo-
cytes according to an established 15-day protocol [28]. 
3T3-L1 cells at the 15th day of differentiation seeded 
on coverslips were washed with PBS and fixed with 4% 
paraformaldehyde for 10  min at room temperature. 
After fixation and further washings with PBS, cells 
were stained with an Oil Red O solution in 40% isopro-
panol. Coverslips were then mounted on microscope 
slides with Vectashield mounting medium with DAPI, 
and images were collected using a Nikon Eclipse E600 
microscope.
Chromatin immunoprecipitation, sequencing and data 
analysis
Chromatin immunoprecipitation was performed 
in mice adipose tissue with a modified protocol as 
described previously [12, 41], using an anti-GFP anti-
body (ab290, Abcam). 10  ng of purified ChIP DNA 
was used as starting material for sequencing librar-
ies preparation. Indexed libraries were prepared with 
TruSeq ChIP Sample Prep Kit (Illumina Inc.). Size dis-
tribution of each ChIP library sample was assessed by 
running a 1 µl aliquot on Agilent High Sensitivity DNA 
chip using an Agilent Technologies 2100 Bioanalyzer 
(Agilent Technologies). The concentration of each sam-
ple was determined by using a Qubit Fluorometer (Life 
Technologies). Libraries were sequenced (single read, 
1  ×  50 cycles) at a concentration of 10  pM/lane on 
HiSeq 2500 (Illumina Inc.). The raw sequence files gen-
erated (fastq) underwent quality control analysis using 
FASTQC (http://www.bioinformatics.babraham.ac.uk/
projects/fastqc/). Reads were aligned to the mus mus-
culus genome (assembly mm10) using Bowtie software, 
allowing up to 2 mismatch and considering uniquely 
mappable reads. Duplicate sequences were removed 
before peaks enrichment calculation using MarkDupli-
cates (Picard Tools; https://broadinstitute.github.io/pic-
ard/). Violin plots representing the density of reads were 
generated with the vioplot package [42]. The enriched 
ChIP-Seq regions were identified using Spatial Cluster-
ing for Identification of ChIP-Enriched Regions (SICER) 
[43] setting standard parameters and a false discovery 
rate of 1%. For each analyzed condition, only regions 
in common between the two biological replicates were 
considered for further analysis. The annotation of peaks 
to the nearest gene was performed using the annotate-
Peaks.pl function from HOMER [44]. Overrepresented 
transcription factor binding sites analysis was per-
formed using PscanChip [45], while annotation plots 
were generated using ChIPseek [46]. Circos plot was 
generated with Circos [47].
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Statistical tests
Results are expressed as mean  ±  S.E.M. Comparisons 
between groups were performed with the parametric 
Student’s t test or the nonparametric Mann–Whitney 
U test, as appropriate, using GraphPad Prism software 
(version 5.00 for Windows, San Diego, CA, USA): A P 
value ≤0.05 was considered significant.
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Tg + INS vs Tg; $P < 0.05 Tg + INS vs WT + INS.
Additional file 4. Figure S3. MacroH2A1.1 and macroH2A1.2 expres-
sion in 3T3-L1 pre-adipocytes and adipocytes. 3T3-L1 pre-adipocytes 
with lentiviral-mediates stable expression of GFP, macroH2A1.1-GFP and 
macroH2A1.2-GFP were induced to differentiate into mature adipocytes 
as in Fig. 6. At the 1st, 5th and 15th day of differentiation, histones were 
extracted and processed for immunoblotting with anti-macroH2A1.1, 
macroH2A1.2 and anti-H3-specific antibodies. Representative blots are 
shown, together with MW ladder.
Additional file 5. Figure S4. Gene expression in 3T3-L1 adipocytes. 
3T3-L1 pre-adipocytes with lentiviral-mediates stable expression of GFP, 
macroH2A1.1-GFP and macroH2A1.2-GFP were induced to differentiate 
into mature adipocytes as in Fig. 6. At the 15th day of differentiation, RNA 
was extracted and processed for qPCR analyses with specific primers. 
Results were normalized to pre-differentiation gene levels. Values are rep-
resented as means (N = 3) ± S.E.M. *P < 0.05; ***P < 0.0001 change vs GFP.
Additional file 6. Figure S5. Representative images of liver (left panels) 
and heart (right panels) sections immunostained for macroH2A1.1 or for 
macroH2A1.2 (green). Both isoforms appear to be highly expressed in 
hepatocytes, whereas there a strong reduction in expression pattern of 
macroH2A1.2 is observed in mouse heart tissue. Nuclei were counter-
stained with DAPI.
Additional file 7. Figure S6. Histogram representing the distance and 
the frequency of macroH2A1.2-binding regions from transcriptional start-
ing site (TSS), genome-wide.
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